Moreover, this effect is consistent with the observation that the addition of cetuximab to high-dose radiotherapy significantly increases the control of regional and distant metastatic disease and survival in patients with locally advanced HNSCC, especially in nonoropharyngeal HPV-negative and HER1-positive tumors, without increasing radiation-associated acute toxicity [8,50]. This evidence concerns the gene EGFR and metastatic neoplasm.